Anbio Biotechnology Class A Ordinary Shares
NNNN · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -60% | 60% | 19.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 84.6% | 66.9% | 42.8% | 58.7% |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -52.4% | 61.5% | 20.2% | 50% |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -52.4% | 61.5% | 20.1% | 49.7% |
| EPS Diluted | -0.031 | 0.092 | 0.019 | 0.039 |
| % Growth | -134.1% | 391.4% | -51.9% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |